Screener
Tango Therapeutics TNGX Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $3.72M+200% | $2.18M+34.9% | $1.68M-7.3% | $1.1M-39.4% | $1.24M-40.2% | ||
| $0-100% | $0-100% | $0-100% | $53.81M+364% | $3.18M-84.0% | ||
| $37.2M+13.4% | $33.53M-8.0% | $32.1M-5.4% | $30.82M-7.4% | $32.81M-15.1% | ||
| $59.79M+35.4% | $48.77M+1.8% | $41.86M-7.0% | $39.74M-10.7% | $44.15M-10.7% | ||
| $4.45M+107% | $3.26M+21.1% | $3.06M-7.0% | $1.8M-52.1% | $2.15M-47.1% | ||
| -$55.34M-42.4% | -$45.51M-14.1% | -$38.75M-2.9% | $15.88M+154% | -$38.85M-52.1% | ||
| -$59.36M-47.1% | -$48.31M-15.3% | -$41.39M-2.7% | $14.63M+145% | -$40.34M-39.5% | ||
| -$59.79M-45.9% | -$48.77M-14.7% | -$41.86M-2.3% | $14.07M+143% | -$40.97M-38.6% |
FAQ
- What is Tango Therapeutics's revenue?
- Tango Therapeutics (TNGX) generated $53.8M in revenue over the trailing twelve months, up 121.5% year over year.
- Is Tango Therapeutics profitable?
- Tango Therapeutics is not currently profitable: it reported a net loss of $123.7M over the trailing twelve months, a -229.9% net margin.
- What is Tango Therapeutics's earnings per share?
- Tango Therapeutics's diluted EPS over the trailing twelve months is $-0.86.
- Where does Tango Therapeutics's income statement data come from?
- Every line is extracted from Tango Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
